- Official Masters eCampus
- eCampus Masters, Postgraduates and Courses
- Timetables and calendars
- Future Students
- Contact information
- About the TecnoCampus Park
- TecnoCampus Facilities
- HUB4T TecnoCampus
- Alumni
- TecnoCampus University Center
- Teaching staff
- Service for Quality and Teaching Innovation
- Library -CRAI
- Host your company
- Communication and press room
- TecnoCampus corporate image
- Events
- Transparency portal
- Equality Unit
- Supplier's Office
- Work with us
- TecnoCampus quality
What are you looking for?
The company based in the TecnoCampus Minoryx has reached one agreement to assign the rights to commercialize its treatment for the minority disease X-ALD in Europe. The agreement is with Neuraxpharm for the drug Leriglitazone, specialized in the treatment of X-linked adrenoleukodystrophy (X-ALD).
Neuraxpharm, a leading European pharmaceutical company specializing in the treatment of CNS disorders, today announced the signing of a strategic licensing agreement. Minoryx grants Neuraxpharm exclusive rights in Europe to lead candidate, leriglitazone, a novel selective brain-penetrating PPAR-gamma agonist. As part of the agreement, Neuraxpharm will pay Minoryx a significant double-digit upfront amount, in addition to milestone payments and development funding totaling up to €258 million. In addition, Minoryx will receive incremental double-digit royalties.
Institution
Study
Become an entrepreneur
TecnoCampus Park Mataró-Maresme
Tel. +34 93 169 65 00
info@tecnocampus.cat
Av. Ernest Lluch, 32 | 08302 Mataró
© 2024 TecnoCampus. All rights reserved.
Web project developed by ACTIUM Digital